Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Thank you BIO, you just did this board

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
Mellowmood77 Member Profile
Member Level 
Followed By 26
Posts 533
Boards Moderated 0
Alias Born 04/30/19
160x600 placeholder
Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Pat... GlobeNewswire Inc. - 10/17/2019 9:49:02 AM
Amarin to Participate in the Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/23/2019 4:15:00 PM
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognize... GlobeNewswire Inc. - 9/16/2019 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/12/2019 6:14:02 AM
New 2019 Updates to the European Society of Cardiology’s and European Atherosclerosis Society’s Guidelines for the Manage... GlobeNewswire Inc. - 9/3/2019 6:00:00 AM
Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire Inc. - 8/28/2019 6:00:00 AM
Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Choles... GlobeNewswire Inc. - 8/27/2019 6:00:00 AM
Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference GlobeNewswire Inc. - 8/21/2019 6:00:00 AM
Amarin (AMRN) Alert: Johnson Fistel Launches Investigation into Amarin Corporation plc; Investors Encouraged to Contact Firm PR Newswire (US) - 8/9/2019 8:53:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 7:22:13 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/31/2019 6:34:48 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/31/2019 6:30:41 AM
Amarin Reports Second Quarter 2019 Financial Results and Operational Update GlobeNewswire Inc. - 7/31/2019 5:00:00 AM
Amarin Announces Underwriters’ Full Exercise of Option to Purchase Additional American Depositary Shares GlobeNewswire Inc. - 7/29/2019 5:17:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/24/2019 4:32:58 PM
Amarin to Report Second Quarter 2019 Results and Host Conference Call on July 31, 2019 GlobeNewswire Inc. - 7/24/2019 6:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/19/2019 5:01:04 PM
Amarin Prices Public Offering of American Depositary Shares GlobeNewswire Inc. - 7/18/2019 11:47:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/17/2019 4:38:44 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/17/2019 4:02:07 PM
Amarin Announces $400,000,000 Public Offering of American Depositary Shares GlobeNewswire Inc. - 7/17/2019 4:01:00 PM
Biotech Companies with Recent and Potential Near-Term Catalysts InvestorsHub NewsWire - 7/15/2019 8:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2019 8:15:19 AM
Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance GlobeNewswire Inc. - 7/2/2019 6:00:00 AM
Amarin’s John Thero Awarded NJ EY Entrepreneur of The Year® 2019 Award for Life Sciences GlobeNewswire Inc. - 6/21/2019 1:39:19 PM
Mellowmood77 Member Level  Thursday, 09/19/19 03:43:24 PM
Re: Biobillionair post# 215127
Post # of 220222 
Thank you BIO, you just did this board a huge service and let me explain why...

Your conversation with JT is very interesting, so is the new guidance for CP’s.

It proves MRC is wrong yet again, claiming that Amarin is withholding material information from shareholders and in breach of SEC violations. Now we know Amarin was in fact not solicited with information by the FDA. This is a big deal.

Now, whether MRC GENUINELY believed Amarin was solicited for information, OR he was just trying to instill fear into investors, does not matter anymore. The truth has been revealed and has crippled MRC.

With this knowledge you’ve provided along with the FDA’s new guidance on CP’s, I believe the FDA, as you stated, was put in bad spot. The CP’s MRC posted was extremely profound and I believe by mandate, the FDA could not ignore them (which is why they issued new guidance).

MRC is definitely working with someone. This is not the act of a lone bandit. I said before many times that I believe MRC is either in bed with hedge funds that want in at a cheaper price or BP who want’s to either derail Vascepa or own it at cheaper valuations.

Someone knew how to game the FDA and they did just that, GAMED them. Didn’t somewhere in the new guidance say something about no longer being allowed to purposely file a LATE CP for the sole purpose of delaying PDUFA? Didn’t RAF say he had a source that the FDA actually felt bad for the late ADCOM and made this apparent to JT? The CP causing a late ADCOM makes the most sense now with this new information.

Remember in my earlier posts I was talking about shakeouts? Just look at what the stock has done in the past 2 months. All the shares that were traded in the 13’s, 14’s, 15’s have quickly been ABSORBED. No 13G’s have been filed by BB which means they did not sell a substantial amount and maybe even bought more. Other institutions have been adding. Look at ORBIMED ADVISORS. They used to own FORTY percent of AMRN before they completely cashed out... they have started to make a position AGAIN.

This has the potential to be a blockbuster drug of ages. It will shake out weak hands AS MUCH AS IT CAN by lowering SP until the only way to get rid of the retail investors is to start RAISING the price.

Will another shakeout happen? Probably. MRC isn’t done as he’s creating another 50+ page report for the ADCOM comment. Will it be as big as the ADCOM announcement? Doubt it.

One thing is for certain. JT telling BIO the reason for PDUFA wasn’t due to solicited information causing an amendment to the sNDA is very good news. Thanks Bio for posting.









Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist